16
Jun

South San Francisco startup Kezar Life Sciences is looking to follow through on some promising programs discovered at Onyx Pharmaceuticals, raising $23 million and securing Amgen’s blessing as it targets autoimmune disease.

…read more

Source: Upstart Kezar wrangles $23M to pick up where Onyx left off

    

0 No comments